左西孟旦联合托伐普坦在急性失代偿性心力衰竭中的应用

发布时间：2018-03-12 13:05

本文选题：失代偿性心力衰竭　切入点：左西孟旦　出处：《实用医学杂志》2017年18期 　论文类型：期刊论文

【摘要】：目的探讨托伐普坦、左西孟旦联合治疗对急性失代偿性心力衰竭患者心功能的影响。方法研究对象为2014年5月至2016年1月期间门诊收治的86例急性失代偿性心力衰竭患者,将患者按门诊号末位数字单双数分为常规组(单数)、治疗组(双数),每组各43例。常规组给予一般药物,治疗组在此基础上加用托伐普坦、左西孟旦,观察患者血浆ET(内皮素)、BNP(脑钠肽)水平变化,评估用药前后患者心功能情况,统计治疗期间不良反应情况。结果入院时,两组血浆内皮素、脑钠肽水平以及心功能指标比较差异无统计学意义(P0.05),用药后,患者各指标均有明显改善,治疗组各指标改善效果优于常规组(P0.05);治疗组不良反应率为7.0%,明显低于常规组16.3%,治疗组治疗期间用药安全性高(P0.05)。结论临床对急性失代偿性心力衰竭治疗时,使用托伐普坦、左西孟旦联合治疗,患者症状改善效果好、用药安全性高。
[Abstract]:Objective to investigate the effects of combined treatment of Torvalptan and levosimendan on cardiac function in patients with acute decompensated heart failure. Methods 86 patients with acute decompensated heart failure were enrolled in this study from May 2014 to January 2016. The patients were divided into two groups according to the last number of outpatient numbers. The patients were divided into routine group (odd number) and treatment group (even number, 43 cases in each group). The routine group was given general medicine, and the treatment group was treated with Tofaputan, left West Mendan. The changes of plasma et (brain natriuretic peptide) were observed, the cardiac function of patients before and after treatment and the adverse reactions during treatment were evaluated. There was no significant difference in the levels of brain natriuretic peptide and cardiac function. The improvement effect of each index in the treatment group was better than that in the routine group (P 0.05), and the adverse reaction rate in the treatment group was 7.0, which was significantly lower than that in the routine group. The safety of the treatment group was higher than that of the control group during the treatment period. Conclusion Tovaptan is used in the treatment of acute decompensated heart failure. Combined treatment with levosimendan, the effect of symptom improvement was good, and the safety of medication was high.
【作者单位】：北京市朝阳区双桥医院心内科;
【基金】：北京市朝阳区科技项目(编号:SF1224)
【分类号】：R541.6

【相似文献】